A phase I/II dose-escalation trial of EPO906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer.


5102 Background: Patients (pts) with newly diagnosed advanced ovarian cancer generally receive a taxane in combination with a platinum agent. However, pts refractory to this therapy have few treatment options. Taxane efficacy can be limited by the development of drug-resistance mechanisms, and taxanes are associated with neutropenia and neuropathies. EPO906… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.